OPEN ORPHAN PLC LS-,001 (CRO.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
As of 11:55AM CEST. Market open.
| Previous Close | 0.1350 |
| Open | 0.1420 |
| Bid | 0.1040 x N/A |
| Ask | 0.1850 x N/A |
| Day's Range | 0.1420 - 0.1450 |
| 52 Week Range | 0.1200 - 0.3240 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafterOCALA, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (H
© 2022 Yahoo. All rights reserved.
